论文部分内容阅读
目的:探讨抗病毒药物联合黄芩苷治疗重症H1N1流感的临床疗效及作用机制。方法:将收治的63例重症H1N1流感患者按照分层随机分组法分为观察组和对照组,对照组给予常规抗病毒药物治疗,观察组给予抗病毒药物联合黄芩苷治疗,观察2组治疗前后临床症状、实验室指标及细胞免疫功能改善情况。结果:观察组肺部影像学检查及临床症状改善情况均显著优于对照组,2组间差异有显著性(P<0.05);观察组细胞免疫功能下降情况得到显著改善,明显优于对照组,2组差异有显著性(P<0.05);观察组临床疗效及实验室检测指标均显著优于对照组,2组间差异有显著性(P<0.05)。结论:抗病毒药物联合黄芩苷能显著改善重症H1N1流感患者临床症状,在提高患者免疫力同时缩短病程,具有重要的临床应用价值。
Objective: To investigate the clinical efficacy and mechanism of antiviral drug combined with baicalin in the treatment of severe H1N1 influenza. Methods: Sixty-three patients with severe H1N1 influenza were divided into observation group and control group according to stratified randomized method. The control group was treated with conventional antiviral drugs. The observation group was treated with antiviral drugs combined with baicalin. Clinical symptoms, laboratory indicators and the improvement of cellular immune function. Results: The lung imaging examination and clinical symptom improvement in the observation group were significantly better than those in the control group, with significant difference between the two groups (P <0.05); the decrease of cellular immune function in the observation group was significantly improved, which was significantly better than the control group (P <0.05). The clinical curative effect and laboratory test indexes in the observation group were significantly better than those in the control group, the difference between the two groups was significant (P <0.05). Conclusion: Antiviral drugs combined with baicalin can significantly improve the clinical symptoms of patients with severe H1N1 influenza, improve patient immunity and shorten the course of disease, has important clinical value.